VXRT Vaxart Inc

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that management will host a conference call on Thursday, February 5, 2015 at 9:00 a.m. EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.

In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international). The live webcast can be accessed under the Investors section of the Company's website at www.biotapharma.com or you may use the link: http://edge.media-server.com/m/p/tqxvzn68.

About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals, Inc. is a company focused on the discovery and development of products to treat serious viral respiratory infectious diseases. The Company currently has two clinical-stage Phase 2 product candidates: (i) laninamivir octanoate, which is being developed as a one-time treatment for influenza A and B infections; and (ii) vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses in development for the treatment of human rhinovirus infected patients with underlying respiratory illnesses, such as moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD). The Company is also conducting IND-enabling studies with BTA-C585, an orally bioavailable F protein inhibitor, in development for the treatment of respiratory syncytial virus infections. For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Pharmaceuticals, Inc.

CONTACT: Joseph M. Patti, PhD
         President and Chief Executive Officer
         (678) 221-3351
         j.patti@biotapharma.com
         
         Sarah McCabe
         Stern Investor Relations, Inc.
         (267) 909-9237
         sarah@sternir.com